Johnson & Johnson said it will move forward with the $2.1 billion sale of its diabetes monitoring unit LifeScan Inc. to Platinum Equity, a private investment firm.
J&J said in March that it had received a $2.1 billion binding offer from Platinum Equity. On Tuesday, it said it had formally accepted that offer. The health-care company said it expects the deal to close by the end of the year.
New Brunswick, New Jersey-based J&J has been selling off smaller units as the health-care conglomerate gets out of businesses where it’s not a leader. Last week, it announced the sale of a sterilization division to Fortive Corp. for $2.7 billion.
More from Bloomberg.com: The $1.4 Trillion U.S. ‘Surplus’ That Trump’s Not Talking About
Medical devices and diagnostics are the second-biggest of J&J’s three major areas, which also include drugs and consumer health products. LifeScan makes the OneTouch brand of diabetes monitors, and the division had $1.62 billion in sales last year.
More from Bloomberg.com
- Landlords Are Practically Giving Malls Away
- U.S. Inflation Accelerates to Six-Year High, Eroding Wages
- Trump Gave Kim a Summit But Left With Little to Show for It
Read J&J Formally Accepts $2.1 Billion Offer for Diabetes Device Unit on bloomberg.com